Haleon plc (LSE/NYSE: HLN), the consumer health company behind brands including Sensodyne, Panadol and Centrum, has announced the aggregated purchase of 11,006,678 ordinary shares between 9 and 13 November 2026, to be held as treasury shares under its share buyback programme launched on 29 October 2026. The shares were purchased exclusively on the London Stock Exchange, with daily volume weighted average prices ranging from 334.27p to 343.10p across the five trading days. The disclosure updates investors on Haleon's total voting share capital and treasury share position following settlement of these transactions.

Key Points

  • Haleon plc (HLN) — listed on the London Stock Exchange and NYSE
  • 11,006,678 ordinary shares purchased between 9–13 November 2026 and designated as treasury shares
  • Highest price paid across the period was 346.00p on 13 November 2026; lowest was 330.00p on 10 November 2026
  • Investors should watch the total treasury share count and remaining buyback capacity as the October 2026 programme continues

Daily Breakdown of Haleon's Share Purchases from 9 to 13 November 2026

Haleon purchased 2,777,756 shares on 9 November 2026 at a volume weighted average price (VWAP) of 335.08p, followed by 2,542,718 shares on 10 November at a VWAP of 334.27p. Activity reduced to 1,816,227 shares on 11 November at 337.53p VWAP, and 1,613,684 shares on 12 November at 343.06p VWAP. The week concluded with 2,256,293 shares acquired on 13 November at a VWAP of 343.10p. All purchases were executed on the London Stock Exchange, and all acquired shares are to be held as treasury shares in line with the programme announced on 29 October 2026.

Haleon's Updated Share Capital and Voting Rights Following Settlement

Following settlement of these transactions, Haleon's registered share capital stands at 8,808,341,409 ordinary shares of £0.01 each. Of these, 39,812,973 shares are now held as treasury shares and therefore carry no voting rights. The company states that the number of ordinary shares with voting rights is 8,768,528,436. Under the FCA's Disclosure Guidance and Transparency Rules, shareholders may use this figure to determine whether they are required to notify an interest, or a change to an interest, in Haleon.

Haleon's Consumer Health Portfolio and Buyback Programme Context

Haleon describes itself as a consumer health company solely focused on everyday health, with a product portfolio spanning six categories: Oral Health, Vitamins Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its brand portfolio includes Advil, Centrum, Panadol, Sensodyne, Voltaren and Theraflu, which the company states are trusted by more than one billion consumers globally. The ongoing buyback programme, initiated on 29 October 2026, represents a capital return mechanism that investors in the consumer health sector may monitor as a signal of management's confidence in the balance sheet.